The patient experience is shaped by more than therapy alone. Education, access, and ongoing support may help patients and care partners navigate the deep brain stimulation (DBS) journey. For a decade, our innovations in DBS therapy have made that experience more connected and manageable. Watch the video to hear from healthcare providers as they share their perspectives on the DBS patient experience. Rebecca Wilkins | Casey Halpern, MD | Drew Falconer, MD | Leo Verhagen, MD, PhD | Michael Soileau, MD FAAN | George Mandybur, MD | Meredith Hatcher, PA-C, CMRD | Andrew Imbus, PA-C Important Safety Info: bit.ly/4gL7p46 #DBS #Neuromodulation MAT-2678704 v3.0 | Item approved for use in the US.

10 years of our deep brain stimulation (DBS) therapy in the US. A decade of progress driven by patient needs and shaped by physician insights. Since 2016, our DBS portfolio has continued to evolve, building on clinical experience, first-of-its-kind innovation like NeuroSphere Virtual Clinic¹, and ultimately shaping the field of DBS to support patients. Watch the video to see what we've done in the past 10 years, featuring Ryan Lakin, Leo Verhagen, MD, PHD, Binith Cheeran, MD, PhD, Drew Falconer, MD, Michael Soileau, MD FAAN, Meredith Hatcher, PA-C, CMRD, and George Mandybur, MD. Important Safety Info: bit.ly/4gL7p46 #DBS #Neuromodulation MAT-2678704 v2.0 | Item approved for use in the US. 1. Abbott. First-of-its-Kind: US Virtual Clinic Neuromodulation Memo. 2021

Innovation matters when it addresses real challenges in clinical practice. Since 2016, our deep brain stimulation (DBS) innovations have continued to advance, with technology designed around the realities of care and the needs of patients and providers throughout the DBS journey. Drew Falconer, MD | Meredith Hatcher, PA-C, CMRD | Leo Verhagen, MD, PhD | Jessica Karl, PhD, PA-C | Casey Halpern, MD | Michael Soileau, MD FAAN | Binith Cheeran, MD, PhD Learn more about Abbott DBS here: bit.ly/3T4ZKUZ Important Safety Info: bit.ly/4gL7p46 #DBS #Neuromodulation MAT-2678704 v3.0 | Item approved for use in the US.

Time burden is an important consideration in deep brain stimulation (DBS) care delivery. In the Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation (ROAM-DBS) study, patients spent an average of 15 hours preparing, traveling, and attending programming sessions.¹ Remote programming sessions, by comparison, averaged about 14 minutes.¹ With NeuroSphere™ Virtual Clinic, clinicians have another way to deliver programming adjustments without adding to the demands of an in-person visit. Talk to your Abbott rep to learn more: https://bit.ly/47CYZ9I Important Safety Info: https://abbo.tt/4qGETCt 1. Gharabaghi, A., Groppa, S., Navas-Garcia, M. et al. Accelerated symptom improvement in Parkinson’s disease via remote internet-based optimization of deep brain stimulation therapy: a randomized controlled multicenter trial. Commun Med 5, 31 (2025). https://lnkd.in/ebVAYhP7

Discover how FlexBurst360™ therapy advances the foundation of BurstDR™ stimulation, offering personalized programming options to help address the needs of patients with multiple site pain and evolving pain patterns.¹⁻²* See the evolution: https://lnkd.in/eZ7_tppy Important Safety Info: https://bit.ly/4gL7p46 Steven Falowski | Iden M. Cowan MD | Pankaj Mehta MD | Jackie Weisbein | Tim Deer, MD #Neuromodulation #Innovation #PainManagement *Programming options are available for patients with multisite pain and evolving pain patterns. 1. Abbott. NeuroSphere Clinician Programmer, Eterna SCS System. 2025. 2. Abbott. NeuroSphere Clinician Programmer Spinal Cord Stimulation Systems Model 3874. 2025. MAT-2677970 v2.0 | Item approved for use in the US.

In the 2026 Medicare Final Physician Fee Schedule published on October 31, 2025, CMS granted permanent Telehealth Status for NeuroSphere™ Virtual Clinic. This solidifies that the future of digital health and connected care is here to stay. Reflecting this progress, the ROAM-DBS clinical study confirms what many suspected: remote DBS programming provides patients faster symptom improvement* approximately 15 days sooner, which was statistically significant, than with standard in-clinic programming alone¹. Connect with your local rep to learn more: http://abbo.tt/4hqGMQt. Important Safety Info: http://bit.ly/3zexfYv.

Managing deep brain stimulation (DBS) care is an ongoing process, where programming adjustments, education, and support shape how patients stay on treatment over time.¹ NeuroSphere™ Digital Health App brings these elements together in one place – from educational resources and ongoing support to remote programming through NeuroSphere™ Virtual Clinic – to help support your patients throughout their DBS therapy journey. Talk to your Abbott rep to learn more: https://bit.ly/47CYZ9I Important Safety Info: https://abbo.tt/4qGETCt 1. Gharabaghi, A., Groppa, S., Navas-Garcia, M. et al. Accelerated symptom improvement in Parkinson’s disease via remote internet-based optimization of deep brain stimulation therapy: a randomized controlled multicenter trial. Commun Med 5, 31 (2025). https://lnkd.in/ebVAYhP7

Technology alone doesn't change a patient's life. The team behind it does. This video features Drew Falconer, MD, Michael Soileau, MD FAAN, Meredith Hatcher, PA-C, CMRD, and Andrew Imbus, PA-C, talking about what DBS education and support look like in their clinics. What I hear from them is a story about collaboration. When a physician has a question in the middle of a programming session, when a clinic is onboarding a new deep brain stimulation (DBS) patient to NeuroSphere™ Virtual Clinic, when a clinic needs a partner who understands the technology inside and out, that's where our Abbott team shows up. Our role isn't just to bring the new technology to the market. It's to deliver ongoing support for our devices alongside clinicians, so they can focus on what matters most: their patients. That partnership is what turns an innovative device into better patient care. It's what gives a physician the confidence to expand DBS therapy to more patients who need it. I'm proud of the team we’ve built and the way they show up for clinics every single day. This video is a window into that work. #AbbottProud #DBS #Neuromodulation Important Safety Info: https://bit.ly/4gL7p46

Innovation that matters. Outcomes that endure.¹ At #ASPN2026, our clinical program will highlight how we’re advancing the way chronic pain is assessed, studied, and managed in real-world practice. Across our moderated sessions, we’ll share new insights focused on scalable data capture, validated outcomes, and long-term clinical benefits. Check out our podium presentations and posters: https://abbo.tt/4wi2Brs #Neuromodulation #ChronicPainManagement 1. Abbott. BurstDR™ Stimulation SCS Clinical Consistency Memo. 2026.

BurstDR™ stimulation continues to demonstrate consistent benefits in pain relief, patient satisfaction, and quality of life. Ongoing clinical research continues to reinforce the consistency of outcomes observed across studies and patient populations.¹⁻²* See how the evidence has evolved: https://lnkd.in/eZ7_tppy Important Safety Info: https://bit.ly/4gL7p46 #Neuromodulation #ClinicalEvidence #ChronicPain 1. Abbott. Clinical Summaries for Spinal Cord Stimulation Systems Clinician’s Manual. 2023. 2. Abbott. BurstDR™ Stimulation SCS Clinical Consistency Memo. 2026. *Abbott Medical spinal cord stimulation (SCS) systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, nonsurgical back pain (without prior surgery and not a candidate for back surgery). Indications for use and labeling for Abbott SCS systems may vary between countries worldwide. Refer to Clinician’s Manual for Indications for Use for all Abbott neuromodulation systems. Not all individual study designs are applicable in all countries/regions. MAT-2677970 v2.0 | Item approved for use in the US.